• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta biomaterialia >Simultaneous drug release at different rates from biodegradable polyurethane foams.
【24h】

Simultaneous drug release at different rates from biodegradable polyurethane foams.

机译：从可生物降解的聚氨酯泡沫中以不同的速率同时释放药物。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this study, we present an approach for the simultaneous release of multiple drug compounds at different rates from single-phase polyurethane foams constructed from lysine diisocyanate (LDI) and glycerol. The anti-cancer compounds DB-67 and doxorubicin were covalently incorporated into polyurethane foams, whereby drug release can then occur in concert with material degradation. To begin, the reactions of DB-67 and doxorubicin with LDI in the presence of a tertiary amine catalyst were monitored with infrared spectroscopy; each compound formed urethane linkages with LDI. Fluorescent spectra of DB-67 and doxorubicin were then recorded in phosphate-buffered saline, pH 7.4 (PBS), to ensure that each anti-cancer compound could be quantitatively detected alone and in combination. Doxorubicin and DB-67 were then incorporated into a series of degradable LDI-glycerol polyurethane foams alone and in combination with one another. The sol content, average porosity and drug distribution throughout each foam sample was measured and found to be similar amongst all foam samples. The stability of DB-67 and doxorubicin's fluorescent signal was then assessed over a 2-week period at 70 degrees C. Release rates of the compounds from the foams were assessed over a 10-week period at 4, 22, 37 and 70 degrees C by way of fluorescence spectroscopy. Release was found to be temperature-dependent, with rates related to the chemical structure of the incorporated drug. This study demonstrates that differential release of covalently bound drugs is possible from simple single-phase, degradable polyurethane foams.
机译：在这项研究中，我们提出了一种从赖氨酸二异氰酸酯（LDI）和甘油构成的单相聚氨酯泡沫中以不同速率同时释放多种药物化合物的方法。将抗癌化合物DB-67和​​阿霉素共价掺入聚氨酯泡沫中，然后药物释放会与材料降解同时发生。首先，用红外光谱监测DB-67和​​阿霉素与LDI在叔胺催化剂存在下的反应。每个化合物都与LDI形成氨基甲酸酯键。然后在pH 7.4的磷酸盐缓冲盐水（PBS）中记录DB-67和​​阿霉素的荧光光谱，以确保可以单独或组合定量检测每种抗癌化合物。然后将阿霉素和DB-67单独并相互结合掺入一系列可降解的LDI-甘油聚氨酯泡沫中。测量了每个泡沫样品中的溶胶含量​​，平均孔隙率和药物分布，发现在所有泡沫样品中相似。然后在70摄氏度下于2周内评估DB-67和​​阿霉素的荧光信号的稳定性。在4、22、37和70摄氏度下于10周内评估泡沫中化合物的释放速率通过荧光光谱法。发现释放是温度依赖性的，速率与所掺入药物的化学结构有关。这项研究表明，可以从简单的单相可降解聚氨酯泡沫中差异释放共价结合的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号